JP2005515162A - マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種 - Google Patents

マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種 Download PDF

Info

Publication number
JP2005515162A
JP2005515162A JP2003509957A JP2003509957A JP2005515162A JP 2005515162 A JP2005515162 A JP 2005515162A JP 2003509957 A JP2003509957 A JP 2003509957A JP 2003509957 A JP2003509957 A JP 2003509957A JP 2005515162 A JP2005515162 A JP 2005515162A
Authority
JP
Japan
Prior art keywords
mycoplasma hyopneumoniae
vaccine
proteins
polypeptides
mycoplasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003509957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515162A5 (enExample
Inventor
ケイチ，ロビン・リー
サバディニ，リサ・グレース
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005515162(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2005515162A publication Critical patent/JP2005515162A/ja
Publication of JP2005515162A5 publication Critical patent/JP2005515162A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003509957A 2001-07-02 2002-06-07 マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種 Pending JP2005515162A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02
PCT/IB2002/002121 WO2003003941A2 (en) 2001-07-02 2002-06-07 One dose vaccination with mycoplasma hyopneumoniae

Publications (2)

Publication Number Publication Date
JP2005515162A true JP2005515162A (ja) 2005-05-26
JP2005515162A5 JP2005515162A5 (enExample) 2006-01-12

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003509957A Pending JP2005515162A (ja) 2001-07-02 2002-06-07 マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種

Country Status (42)

Country Link
US (3) US6846477B2 (enExample)
EP (3) EP2027873B8 (enExample)
JP (1) JP2005515162A (enExample)
KR (1) KR20040030785A (enExample)
CN (3) CN101524532B (enExample)
AP (1) AP2003002937A0 (enExample)
AR (1) AR034678A1 (enExample)
AT (1) ATE412426T2 (enExample)
AU (1) AU2002309109B2 (enExample)
BG (1) BG66481B1 (enExample)
BR (1) BR0210804A (enExample)
CA (1) CA2451626C (enExample)
CY (1) CY1108749T1 (enExample)
CZ (1) CZ305781B6 (enExample)
DE (1) DE60229666D1 (enExample)
DK (3) DK2842569T3 (enExample)
DO (1) DOP2002000431A (enExample)
EA (1) EA009901B1 (enExample)
ES (3) ES2550458T3 (enExample)
GT (1) GT200200138A (enExample)
HK (1) HK1207584A1 (enExample)
HR (1) HRP20031079A2 (enExample)
HU (1) HU230246B1 (enExample)
IL (1) IL159349A0 (enExample)
IS (1) IS7076A (enExample)
MA (1) MA27047A1 (enExample)
MX (1) MXPA03011599A (enExample)
NO (1) NO342654B1 (enExample)
NZ (1) NZ530106A (enExample)
OA (1) OA12638A (enExample)
PA (1) PA8549701A1 (enExample)
PE (1) PE20030285A1 (enExample)
PL (1) PL209773B1 (enExample)
PT (3) PT2842569T (enExample)
SK (1) SK288010B6 (enExample)
TN (1) TNSN03155A1 (enExample)
TW (1) TWI329514B (enExample)
UA (1) UA78707C2 (enExample)
UY (1) UY27366A1 (enExample)
WO (1) WO2003003941A2 (enExample)
YU (1) YU102203A (enExample)
ZA (1) ZA200309698B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520771A (ja) * 2008-01-23 2011-07-21 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
JP2015052613A (ja) * 2010-08-27 2015-03-19 インターベット インターナショナル ベー． フェー． ワクチン製剤についての効力試験
JP2016538846A (ja) * 2013-11-21 2016-12-15 アグリカルチュラル テクノロジー リサーチ インスティテュート マイコプラズマ属菌種の感染を予防する組成物
KR20180074804A (ko) 2009-06-04 2018-07-03 고쿠리츠칸센쇼켄쿠죠 마이코플라즈마 감염증용 백신

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (en) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Multiple-strain mycoplasma hyopneumoniae vaccines
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
ES2553254T3 (es) 2005-12-29 2015-12-07 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunogénica de PCV2 para reducir los síntomas clínicos en cerdos
CN102698263B (zh) 2005-12-29 2016-07-06 贝林格尔.英格海姆维特梅迪卡有限公司 多价pcv2免疫原性组合物和制备此类组合物的方法
BRPI0708522A2 (pt) * 2006-03-03 2011-05-31 Merial Ltd vacina de mycoplasma hyopneumoniae
EP2099927A4 (en) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
RU2520087C2 (ru) 2006-12-15 2014-06-20 Бёрингер Ингельхайм Ветмедика, Инк. Лечение свиней с помощью антигена pcv2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR101225304B1 (ko) 2007-11-06 2013-01-22 와이어쓰 엘엘씨 마이코플라스마 하이오뉴모니아에 비독성 항원보강된 살아있는 백신
WO2009088950A2 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 virus like particle with foreign amino acid insertion
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
EP3725328A3 (en) * 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
ES2559445T3 (es) 2010-05-11 2016-02-12 Intervet International B.V. Vacuna contra Mycoplasma hyopneumoniae apta para la administración en presencia de anticuerpos de origen materno
RU2722357C2 (ru) * 2010-07-26 2020-05-29 Кью Байолоджикс Инк. Иммуногенные противовоспалительные композиции
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
BR112014022067B1 (pt) * 2012-03-07 2022-05-31 Ceva Sante Animale Composição compreendendo antígeno e lipopolissacarídeo
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA121193C2 (uk) 2012-12-28 2020-04-27 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання імуногенної композиції проти мікоплазми
KR102355614B1 (ko) 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
MX355078B (es) * 2013-02-05 2018-04-03 Agricultural Tech Res Inst Vacuna de subunidades anti-mycoplasma spp.
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
WO2015042369A2 (en) 2013-09-19 2015-03-26 Zoetis Llc Oil-based adjuvants
MX373884B (es) 2013-10-02 2020-03-26 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
CN114699518B (zh) 2015-01-16 2024-07-02 硕腾服务有限责任公司 口蹄疫疫苗
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
US10519199B2 (en) * 2016-08-12 2019-12-31 Innovac Vaccine composition comprising recombinant protein for preventing swine Mycoplasma infection
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283840A3 (en) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
US5252328A (en) 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
DE3881993T2 (de) 1987-09-18 1993-09-30 Akzo Nv Mycoplasma-Impfstoff.
HUT65827A (en) 1990-04-02 1994-07-28 Synergen Inc Polypeptides useful in animal treatment against mycoplasma infections
EP0597852B2 (en) 1990-05-29 2005-08-10 Wyeth Holdings Corporation Swine pneumonia vaccine and method for the preparation thereof
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (en) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. DNA's encoding surface antigen of mycoplasma hyopneumoniae, DNA fragments for primer, recombinant antigenic peptides and diagnostic method of mycoplasmal pneumoniae of swine using same
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
AU687750B2 (en) * 1992-09-28 1998-03-05 Wyeth Holdings Corporation Method of enhancing cell mediated immune responses
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (en) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. Characterization of mycoplasma hyopneumoniae adhesins
ATE365049T1 (de) 1994-05-10 2007-07-15 Wyeth Corp Abgeänderter, verbesserter brsv lebend- impfstoff
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
ES2224273T3 (es) 1996-09-30 2005-03-01 University Of Arkansas Metodo para producir inmunidad activa por medio de un conjugado de vacuna.
EP0846468B1 (en) 1996-12-05 2004-06-09 Akzo Nobel N.V. Non-virulent mycoplasma synoviae and vaccine thereof
KR20010032493A (ko) 1997-11-26 2001-04-25 아이오와 스테이트 유니버시티 리서치 파운데이션, 인코퍼레이티드 재조합 미코플라스마 히오뉴모니아(Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ) 백신
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520771A (ja) * 2008-01-23 2011-07-21 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
KR20180074804A (ko) 2009-06-04 2018-07-03 고쿠리츠칸센쇼켄쿠죠 마이코플라즈마 감염증용 백신
JP2015052613A (ja) * 2010-08-27 2015-03-19 インターベット インターナショナル ベー． フェー． ワクチン製剤についての効力試験
JP2016538846A (ja) * 2013-11-21 2016-12-15 アグリカルチュラル テクノロジー リサーチ インスティテュート マイコプラズマ属菌種の感染を予防する組成物

Also Published As

Publication number Publication date
US20030109473A1 (en) 2003-06-12
CZ20033466A3 (cs) 2005-06-15
SK288010B6 (sk) 2012-10-02
PA8549701A1 (es) 2003-01-24
DK1474067T3 (da) 2008-12-08
EP1474067A4 (en) 2005-08-10
CZ305781B6 (cs) 2016-03-16
WO2003003941A2 (en) 2003-01-16
EP2027873B8 (en) 2015-11-11
AP2003002937A0 (en) 2003-12-31
ZA200309698B (en) 2014-04-30
ATE412426T2 (de) 2008-11-15
NO342654B1 (no) 2018-06-25
HK1134900A1 (zh) 2010-05-20
CN1551781B (zh) 2013-01-02
PL373367A1 (en) 2005-08-22
EP2842569A1 (en) 2015-03-04
HK1180224A1 (zh) 2013-10-18
KR20040030785A (ko) 2004-04-09
PT2027873E (pt) 2015-11-03
ES2550458T3 (es) 2015-11-10
BG66481B1 (bg) 2015-02-27
EP2027873B1 (en) 2015-09-09
MA27047A1 (fr) 2004-12-20
PT2842569T (pt) 2019-06-17
TNSN03155A1 (fr) 2005-12-23
TWI329514B (en) 2010-09-01
PT1474067E (pt) 2008-11-14
CN101524532A (zh) 2009-09-09
YU102203A (sh) 2006-05-25
EP2842569B1 (en) 2019-04-10
DOP2002000431A (es) 2003-01-15
ES2312580T3 (es) 2009-03-01
CN102872456B (zh) 2016-01-20
HK1207584A1 (en) 2016-02-05
USRE44399E1 (en) 2013-07-30
EP1474067A2 (en) 2004-11-10
EP1474067B2 (en) 2017-08-16
AU2002309109B2 (en) 2007-12-13
NZ530106A (en) 2007-06-29
BG108546A (bg) 2005-02-28
IS7076A (is) 2003-12-15
CA2451626C (en) 2011-05-31
DK2027873T3 (en) 2015-11-09
CN102872456A (zh) 2013-01-16
EA200301323A1 (ru) 2005-06-30
GT200200138A (es) 2003-05-15
SK15792003A3 (sk) 2005-09-08
AR034678A1 (es) 2004-03-03
NO20035762L (no) 2004-02-02
DK2842569T3 (da) 2019-05-20
HRP20031079A2 (en) 2005-10-31
EP2027873A1 (en) 2009-02-25
UA78707C2 (en) 2007-04-25
PL209773B1 (pl) 2011-10-31
CN1551781A (zh) 2004-12-01
CA2451626A1 (en) 2003-01-16
US6846477B2 (en) 2005-01-25
BR0210804A (pt) 2005-05-03
CY1108749T1 (el) 2014-04-09
HK1068250A1 (en) 2005-04-29
CN101524532B (zh) 2014-03-19
EA009901B1 (ru) 2008-04-28
OA12638A (en) 2006-06-15
PE20030285A1 (es) 2003-03-27
US20050013823A1 (en) 2005-01-20
HUP0400434A2 (en) 2007-08-28
EP1474067B1 (en) 2008-10-29
WO2003003941A3 (en) 2004-07-29
DK1474067T4 (en) 2017-10-16
HU230246B1 (hu) 2015-11-30
MXPA03011599A (es) 2005-03-07
IL159349A0 (en) 2004-06-01
ES2729579T3 (es) 2019-11-04
UY27366A1 (es) 2003-04-30
DE60229666D1 (de) 2008-12-11
ES2312580T5 (es) 2017-12-11

Similar Documents

Publication Publication Date Title
USRE44399E1 (en) One dose vaccination with Mycoplasma hyopneumoniae
AU2002309109A1 (en) One dose vaccination with mycoplasma hyopneumoniae
US20030064079A1 (en) Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
HK1180224B (en) One dose vaccination with mycoplasma hyopneumoniae
HK1134900B (en) One dose vaccination with (1) mycoplasma hyopneumoniae (/1)
HK1068250B (zh) 单剂量猪肺炎支原体疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070704

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080529

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110915